GPR4 and colitis: Based on these research findings, we propose that GPR4 inhibition (e.g., via small-molecule antagonists, siRNAs, antisense oligonucleotides, and antibodies) can be explored as a potential therapeutic approach for colitis treatment and CAC prevention in IBD patients by alleviating chronic intestinal inflammation and inhibiting pathological angiogenesis.